All things considered, this study identifies compound 11b as a strong dual c-Met/VEGFR-2 inhibitor and a promising chemotherapeutic lead candidate for the treatment of breast cancer, highlighting the need for further research into its in vivo effectiveness, selectivity profile, and potential combination regimens. This evidence concerns the gene MET and breast cancer.